287 related articles for article (PubMed ID: 11098314)
21. [A pharmacoeconomic study of in-hospital treatment against community-acquired pneumonia].
Bermejo Vicedo T; Torralba Arranz A; Hidalgo Correas FJ; Millán Santos I; Rodríguez Morradan B
Farm Hosp; 2004; 28(1):29-35. PubMed ID: 15012176
[TBL] [Abstract][Full Text] [Related]
22. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia.
Frank E; Liu J; Kinasewitz G; Moran GJ; Oross MP; Olson WH; Reichl V; Freitag S; Bahal N; Wiesinger BA; Tennenberg A; Kahn JB
Clin Ther; 2002 Aug; 24(8):1292-308. PubMed ID: 12240780
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
Zervos M; Mandell LA; Vrooman PS; Andrews CP; McIvor A; Abdulla RH; de Caprariis PJ; Knirsch CA; Amsden GW; Niederman MS; Lode H
Treat Respir Med; 2004; 3(5):329-36. PubMed ID: 15606222
[TBL] [Abstract][Full Text] [Related]
24. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
File TM; Milkovich G; Tennenberg AM; Xiang JX; Khashab MM; Zadeikis N
Curr Med Res Opin; 2004 Sep; 20(9):1473-81. PubMed ID: 15383197
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of the efficiency of antimicrobial treatment for community-acquired pneumonia in clinical practice].
Zhukova OV; Ruina OV; Kononova SV; Konyshkina TM
Ter Arkh; 2017; 89(8):17-21. PubMed ID: 28914846
[TBL] [Abstract][Full Text] [Related]
26. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
Dresser LD; Niederman MS; Paladino JA
Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
[TBL] [Abstract][Full Text] [Related]
28. Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?
Brown PD
Pharmacoeconomics; 2004; 22(7):413-20. PubMed ID: 15137880
[TBL] [Abstract][Full Text] [Related]
29. Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
Marrie TJ
Chemotherapy; 2004; 50 Suppl 1():11-5. PubMed ID: 15319549
[TBL] [Abstract][Full Text] [Related]
30. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Griffin AT; Peyrani P; Wiemken T; Arnold F
Int J Tuberc Lung Dis; 2010 Apr; 14(4):495-9. PubMed ID: 20202309
[TBL] [Abstract][Full Text] [Related]
31. [Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization].
Geijo Martínez MP; Díaz de Tuesta Chow-Quan AM; Herranz CR; Gómez Criado C; Dimas Nuñez JF; Saiz García F
An Med Interna; 2002 Dec; 19(12):621-5. PubMed ID: 12593029
[TBL] [Abstract][Full Text] [Related]
32. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia.
Norrby SR; Petermann W; Willcox PA; Vetter N; Salewski E
Scand J Infect Dis; 1998; 30(4):397-404. PubMed ID: 9817522
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
34. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
Mokabberi R; Haftbaradaran A; Ravakhah K
J Clin Pharm Ther; 2010 Apr; 35(2):195-200. PubMed ID: 20456738
[TBL] [Abstract][Full Text] [Related]
35. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
[TBL] [Abstract][Full Text] [Related]
36. Inpatient care of community-acquired pneumonia: the effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals.
Marras TK; Jamieson L; Chan CK
Can Respir J; 2004 Mar; 11(2):131-7. PubMed ID: 15045044
[TBL] [Abstract][Full Text] [Related]
37. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia.
Shorr AF; Zadeikis N; Xiang JX; Tennenberg AM; Wes Ely E
Clin Ther; 2005 Aug; 27(8):1251-9. PubMed ID: 16199249
[TBL] [Abstract][Full Text] [Related]
38. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia.
Gilbert K; Gleason PP; Singer DE; Marrie TJ; Coley CM; Obrosky DS; Lave JR; Kapoor WN; Fine MJ
Am J Med; 1998 Jan; 104(1):17-27. PubMed ID: 9528715
[TBL] [Abstract][Full Text] [Related]
39. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database.
Brown RB; Iannini P; Gross P; Kunkel M
Chest; 2003 May; 123(5):1503-11. PubMed ID: 12740267
[TBL] [Abstract][Full Text] [Related]
40. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
Croom KF; Goa KL
Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
